Delving into the Latest Updates on Mucos Pharma GmbH & Co. KG with Synapse

Overview

The aim of the current study is to investigate the therapeutic effect and especially the mode of action of Wobenzym® plus, an anti-inflammatory drug containing proteolytic enzymes, on exercise induced muscle damage (eiMD) and recovery time in male amateur sportsmen with medium proficiency level compared to placebo.

Start Date01 Feb 2013

Sponsor / Collaborator

Mucos Pharma GmbH & Co. KG

100 Clinical Results associated with Mucos Pharma GmbH & Co. KG

Login to view more data

0 Patents (Medical) associated with Mucos Pharma GmbH & Co. KG

Login to view more data

4

Literatures (Medical) associated with Mucos Pharma GmbH & Co. KG

01 Mar 2017·BMJ Open Sport & Exercise Medicine

Effects of a systemic enzyme therapy in healthy active adults after exhaustive eccentric exercise: a randomised, two-stage, double-blinded, placebo-controlled trial

Article

Author: Marzin, Tobias ; Lorkowski, Gerhard ; Pabst, Elisabeth ; Pabst, Helmut ; Reule, Claudia ; Rau, Stefanie ; Vester, Johannes C

BackgroundSystemic enzyme therapy may improve symptoms of exhaustive eccentric exercise due to anti-inflammatory properties.MethodsIn a randomised, placebo-controlled, two-stage clinical trial, systemic enzyme therapy (Wobenzym) was administered for 72 hours before and 72 hours following a day on which subjects performed an exhaustive eccentric exercise (isokinetic loading of the quadriceps). Efficacy criteria (maximal strength and pain) and time points were selected to account for the multidimensional nature of exercise-induced muscle damage symptoms. Subjects were randomised in a crossover (stage I, n=28) and parallel group design (stage II, n=44).ResultsAnalysis of stage I data demonstrated a significant superiority (Mann-Whitney=0.6153; p=0.0332; one sided) for systemic enzyme therapy compared with placebo. Stage II was designed as a randomised controlled parallel group comparison. Heterogeneity (I2>0.5) between stages led to separate analyses of stage I (endurance-trained subjects) and stage II (strength-trained subjects). Combined analysis resulted in no evidence for corresponding treatment effects. Analysis of pooled biomarker data, however, demonstrated significant favourable effects for systemic enzyme therapy in both stages.ConclusionSystemic enzyme therapy before and after exhaustive eccentric exercise resulted in higher maximal concentric strength in the less strength-trained subjects (stage I) and in significant favourable effects on biomarkers (inflammatory, metabolic and immune) in all subjects. The application of these findings needs further evaluation.

31 Jan 2015·Arthritis

The Safety and Efficacy of an Enzyme Combination in Managing Knee Osteoarthritis Pain in Adults: A Randomized, Double-Blind, Placebo-Controlled Trial

Article

Author: Bolten, Wolfgang W. ; Glade, Michael J. ; Ritz, Barry W. ; Raum, Sonja

This randomized, double-blind, placebo-controlled, and comparator-controlled trial evaluated the safety and efficacy of an enzyme combination, as Wobenzym, in adults with moderate-to-severe osteoarthritis (OA) of the knee. Adults (n=150) received Wobenzym, diclofenac (a nonsteroidal anti-inflammatory drug, NSAID), or placebo for 12 weeks. Improvement in pain scores (Lequesne Functional Index) did not differ between subjects treated with Wobenzym or diclofenac, and both treatment groups improved compared to placebo (P<0.05). Reduction in total WOMAC scores (secondary outcome measure) did not differ between Wobenzym and diclofenac, although only diclofenac emerged as different from placebo (P<0.05). The median number of rescue medication (paracetamol) tablets consumed was less in the Wobenzym group compared to placebo (P<0.05), while there was no difference between diclofenac and placebo. Adverse events were similar in frequency in Wobenzym and placebo groups (7.2% and 9.1% of subjects, resp.) and higher in diclofenac group (15.6%). Wobenzym is comparable to the NSAID diclofenac in relieving pain and increasing function in adults with moderate-to-severe painful knee OA and reduces reliance on analgesic medication. Wobenzym is associated with fewer adverse events and, therefore, may be appropriate for long-term use.

International Journal of Immunotherapy

Oral enzyme therapy in hepatitis C patients

Author: Kabil, S. ; Stauder, G.

In an open, randomized, clin. pilot trial, four groups with 20 hepatitis C patients each were treated with either "liver support" therapy, with established medications (one group with ribavirin, one group with α-interferon), or with a novel oral test drug, Phlogenzym, a combination of hydrolytic enzymes with the flavonoid rutosid.The liver transaminases, AST, ALT, and S-γ-GT markedly improved over the period of three months in the three drug groups, but only marginally in the liver support group.The best results were found with Phlogenzym, which was even superior to ribavirin and α-interferon.The tolerance of the oral enzymes was excellent.Further clin. trials with longer observation times, greater numbers of patients, double-blind and partly placebo-controlled, are under way.

100 Deals associated with Mucos Pharma GmbH & Co. KG

Login to view more data

100 Translational Medicine associated with Mucos Pharma GmbH & Co. KG

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data